当前位置:首页>产品中心>单抗/多抗>Anti-Human TNFA & IL17A Bispecific Reference Antibody|抗人TNFα和IL-17A双特异性参考抗体(靶标:人肿瘤坏死因子α/白细胞介素-17A)

Anti-Human TNFA & IL17A Bispecific Reference Antibody|抗人TNFα和IL-17A双特异性参考抗体(靶标:人肿瘤坏死因子α/白细胞介素-17A)

  • 货号:RB9THS856096
  • 价格:面议
  • 点击:283
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型[VH-VH'-H-Gamma1-VL-VL'-C-kappa]-dimer
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1 mg/ml
内毒素水平Please contact with the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a,
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
表达系统Mammalian Cells
登录号Q16552 & P01375
背景信息Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research.
别名Bispecific, A-1230717, ABT-122, 1791410-27-9
种属Human
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 537
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 526
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 448
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 591
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 658
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 656
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 367
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 408
Anti-Burosumab Non-Neutralizing Recombinant Antibody|抗布罗索尤单抗非中和重组抗体(靶标:布罗索尤单抗非中和抗体) 483
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 521
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 467
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 647
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 571
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 588
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 584
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 569
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 343
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 444
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 425
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 325
总计 33037 个记录,共 1652 页,当前第 1644 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00